Overview

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Status:
Not yet recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ibrutinib is a first in class Bruton tyrosine kinase inhibitor (BTKi), for the treatment of B-cell malignancies. This study is being done to determine if taking ibrutinib after contracting COVID-19 will make symptoms better or worse.

Phase:

Phase 2

Details

Lead Sponsor:

Academic and Community Cancer Research United

Collaborator:

National Cancer Institute (NCI)